Investor Presentation
Cadila Healthcare Ltd has informed BSE that the Company is going to participate in IIFL Investor Conference scheduled to be held on February 22, 2017.21-02-2017
21-02-2017
Fixes Record Date for Interim Dividend
Cadila Healthcare Ltd has informed BSE that the Company has fixed March 17, 2017 as the Record Date for the purpose of Payment of Interim Dividend, if declared.20-02-2017
Cadila Healthcare regains glow as Moraiya gets USFDA green light
Cadila share rose by 25% over two days after its Moraiya facility passed an inspection by the US drug regulator20-02-2017
Board to consider Interim Dividend
Cadila Healthcare Ltd has informed BSE that a meeting of the Board of Directors of the Company is scheduled to be held on March 07, 2017, to consider, the proposal of declaration of Interim Dividend, if any, for the financial year 2016-2017.Further, as per Code of Conduct for prevention of Insider Trading adopted by the Company under SEBI [Prohibition of Insider Trading] Regulations, 2015, the Trading Window will remain closed from February...18-02-2017
Cadila shares extend gains; up nearly 5%
Cadila Healthcare surged nearly 5 per cent today, extending its gains for the second session, after the company said the USFDA has inspected its Moraiya plant and found the unit complying with...17-02-2017
Cadila shares extend gains; surge nearly 5%
USFDA has inspected its Moraiya plant and found the unit complying with manufacturing norms17-02-2017
Zydus receives final approval from the USFDA for Fluconazole Tablets USP and Clobetasol Propionate Spray
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated February 17, 2017, titled "Zydus receives final approval from the USFDA for Fluconazole Tablets USP and Clobetasol Propionate Spray".17-02-2017
USFDA Inspection
Cadila Healthcare Ltd has informed BSE that the USFDA inspected Company's Moraiya facility from February 6, 2017 to February 15, 2017.At the end of the inspection, no observation (483) is issued.16-02-2017
Cadila Healthcare's Q3 net profit plunges 35% on subdued sales
Cadila Healthcare's third-quarter net profit declines after US sales dipped 17.2% year-on-year to Rs886.9 crore because of pricing pressure and regulatory issues at its Moraiya plant in Gujarat31-01-2017
Announces Q3 results (Standalone & Consolidated) & Limited Review Report (Standalone & Consolidated) for the Quarter ended December 31, 2016
Cadila Healthcare Ltd has announced the following results for the quarter ended December 31, 2016 The Unaudited Standalone results for the Quarter ended December 31, 2016:The Company has posted a net profit of Rs. 539 million for the quarter ended December 31, 2016 as compared to Rs. 4839 million for the quarter ended December 31, 2015. Total Income has decreased from Rs. 18146 million for the quarter ended December 31, 2015 to Rs....31-01-2017